MetaVia Stock Slips Again Before a Big Obesity-Drug Week
MetaVia Inc. shares fell 1.1% to $2.65 in pre-market trading Thursday, extending a drop of about 20% since May 27, when the company released higher-dose DA-1726 data. Investors await ADA poster presentations on June 7 and a June 8 shareholder vote on a reverse-split proposal. The stock remains volatile as the company’s obesity-drug candidate advances through early trials.